Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Bourdin A, Fabry-Vendrand C, Ostinelli J, et al. The burden of severe asthma in France: a Case-Control Study using a medical claims database. J Allergy Clin Immunol Pract. 2019;7(5):1477–1487. doi:10.1016/j.jaip.2018.12.029
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622–639. doi:10.1183/13993003.00853-2015
   PubMed Web of Science ®Google Scholar
• Navines-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martin M. IgE-related chronic diseases and anti-ige-based treatments. J Immunol Res. 2016;2016:8163803. doi:10.1155/2016/8163803
   PubMed Web of Science ®Google Scholar
• Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol. 2001;107(3):429–440. doi:10.1067/mai.2001.113759
   PubMed Web of Science ®Google Scholar
• Humbert M, Bousquet J, Bachert C, et al. IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418–1429. doi:10.1016/j.jaip.2019.02.030
   PubMed Web of Science ®Google Scholar
• Hose AJ, Depner M, Illi S, et al. Latent class analysis reveals clinically relevant atopy phenotypes in 2 birth cohorts. J Allergy Clin Immunol. 2017;139(6):1935–1945e1912. doi:10.1016/j.jaci.2016.08.046
   Web of Science ®Google Scholar
• Zoratti EM, Krouse RZ, Babineau DC, et al. Asthma phenotypes in inner-city children. J Allergy Clin Immunol. 2016;138(4):1016–1029. doi:10.1016/j.jaci.2016.06.061
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160–167. doi:10.1016/S1081-1206(10)62171-0
   PubMed Web of Science ®Google Scholar
• Cusack RP, Sahadevan A, Lane SJ. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a Real Life Observational Study. QJM. 2016;109(9):601–604. doi:10.1093/qjmed/hcw027
   Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116e111. doi:10.1016/j.jaci.2012.07.047
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. doi:10.1111/j.1365-2222.2008.03121.x
   PubMed Web of Science ®Google Scholar
• Labrosse R, Graham F, Des Roches A, Begin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65(3):189–199. doi:10.1007/s00005-016-0420-z
   PubMed Web of Science ®Google Scholar
• Li JX, Fan LC, Li MH, Cao WJ, Xu JF. Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature. Respir Med. 2017;122:33–42. doi:10.1016/j.rmed.2016.11.019
   PubMed Web of Science ®Google Scholar
• Masieri S, Cavaliere C, Begvarfaj E, Rosati D, Minni A. Effects of omalizumab therapy on allergic rhinitis: a Pilot Study. Eur Rev Med Pharmacol Sci. 2016;20(24):5249–5255.
   Web of Science ®Google Scholar
• Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21(4):428–432. doi:10.2500/ajr.2007.21.3060
   PubMedGoogle Scholar
• Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31(1):76–83. doi:10.2500/aap.2010.31.3304
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a Pilot Study. Allergy Asthma Proc. 2008;29(5):530–537. doi:10.2500/aap.2008.29.3160
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–825. doi:10.1136/thx.2010.152835
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717. doi:10.1111/j.1398-9995.2004.00550.x
   PubMed Web of Science ®Google Scholar
• Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR Study. Eur Respir J. 2018;51(5):1702523. doi:10.1183/13993003.02523-2017
   PubMed Web of Science ®Google Scholar
• Sese L, Schneider M, Bourgoin M, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy. 2019;49(5):733–735. doi:10.1111/cea.13373
   PubMed Web of Science ®Google Scholar
• Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524–532.e2. doi:10.1016/j.anai.2017.09.056
   PubMed Web of Science ®Google Scholar
• Balbino B, Conde E, Marichal T, Starkl P, Reber LL. Approaches to target IgE antibodies in allergic diseases. Pharmacol Ther. 2018;191:50–64.
   PubMed Web of Science ®Google Scholar
• Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103(8):1098–1113. doi:10.1016/j.rmed.2009.03.008
   PubMed Web of Science ®Google Scholar
• Colodenco D, Palomares O, Celis C, Kaplan A, Domingo C. Moving toward consensus on diagnosis and management of severe asthma in adults. Curr Med Res Opin. 2018;34(3):387–399. doi:10.1080/03007995.2017.1380617
   PubMed Web of Science ®Google Scholar
• Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic participants (OUtMATCH). ClinicalTrials.gov identifier: NCT03881696. Available from: https://clinicaltrials.gov/ct2/show/NCT03881696. Accessed February 16, 2021.
   Google Scholar
• Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2019;174(1):29–37. doi:10.1001/jamapediatrics.2019.4476
   Web of Science ®Google Scholar
• Holm JG, Thomsen SF. Omalizumab for atopic dermatitis: evidence for and against its use. G Ital Dermatol Venereol. 2019;154(4):480–487. doi:10.23736/S0392-0488.19.06302-8
   PubMed Web of Science ®Google Scholar